# Progress Note 06 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sir John Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX005-SYN
- Date: 2026-04-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashby-Nwankwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Eight-week review with the exercise treadmill test. **S**

## History of present illness

Sir John has been back to his usual walks of three to four miles, with hills, for more than three weeks, and the cough has gone. His home readings over the past week average 127/79 on amlodipine 5 mg, with no side effects. He has lost 3.2 kg since intake and his waist is down 4 cm. He had a symptom-limited exercise treadmill test this morning. His fecal immunochemical test and his HIV, hepatitis C and hepatitis B screening tests were negative, and he has had both rabies doses. He has been fitted for cold-weather clothing and has gone through the expedition's food lists with the purser. **S**

| Element | Detail |
|---|---|
| Home readings | Seven-day average 127/79 mmHg |
| Weight | 87.6 kg, from 90.8 at intake |
| Exercise test | 9 minutes of the Bruce protocol, about 10 METs; no ischemia |
| Screening | Fecal immunochemical test, HIV, hepatitis C and hepatitis B screening negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good |
| Respiratory | Negative | Cough gone |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Musculoskeletal | Negative | Knees comfortable on hills |

4 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet once daily **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 87.6 kg; BMI 30.3 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), second of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/78, pulse 70; weight 87.6 kg, BMI 30.3; waist 102 cm |
| Cardiovascular | Regular rhythm; no murmur; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Essential hypertension on amlodipine** (I10). At goal: home average 127/79 and office 128/78 on amlodipine 5 mg, helped by weight loss and less wine. Exercise test normal: about 10 METs, normal blood pressure response and no ischemia, so there is no cardiac limit on strenuous work. **S**
   - Continue amlodipine 5 mg; a three-year supply to be dispensed at the pre-departure visit.
   - Home monitor and spare cuff to travel with him; weekly readings on board, and the dose plan in writing for the ship's surgeons.
2. **Obesity, class 1** (E66.811). 3.2 kg lost by his own plan; he wants to keep up daily exercise on board. **S**
   - Continue walking and portion control; deck exercise routine on board.
3. **Expedition preparation** (Z71.84). Cleared for strenuous work; cold-weather clothing fitted; food lists reviewed. **S**
   - Second hepatitis B dose today.
   - Pre-departure visit two weeks before sailing.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, five minutes' rest, large cuff, average of two readings) | Every visit | Completed today | 128/78 mmHg |
| Self-management | Home blood pressure monitoring | At diagnosis and two to four weeks after each treatment change, then weekly | Completed today | Average 127/79 mmHg: at goal |
| Examination | Weight, BMI and waist | Every visit | Completed today | 87.6 kg, BMI 30.3, waist 102 cm |
| Examination | Cardiac auscultation | Every visit | Completed today | No murmur or gallop |
| Medication safety | Amlodipine safety: ankle swelling, dizziness, flushing | At each visit | Completed today | No ankle swelling or dizziness |
| Examination | Exercise treadmill test before strenuous remote work | Before clearance | Completed today | About 10 METs; peak heart rate 152; normal blood pressure response; no ischemia or arrhythmia |
| Laboratory | Basic metabolic panel, potassium and eGFR | Yearly (every six months only on a diuretic or renin-angiotensin blocker) | Due | A baseline before departure at the next visit |
| Self-management | Cold injury and hypothermia prevention | Before departure | Completed today | Layered clothing with vapor control fitted; buddy checks, dry socks and mitts, and frostbite and hypothermia first aid reviewed |
| Self-management | Nutrition and food safety for the expedition (vitamin C and D, rations, cans, lead, botulism) | Before departure | Completed today | Food lists reviewed: canned food from suppliers without lead solder; damaged or bulging cans discarded unopened; vitamin C tablets in sealed storage |

## Goal progress

- Confirm or exclude hypertension with a week of home readings. Outcome by 2026-01-27: Home average 144/90 mmHg: stage 2 hypertension confirmed. **S**
- Blood pressure below 130/80 mmHg at home before departure. Outcome by 2026-04-07: Home average 127/79 mmHg at eight weeks on amlodipine 5 mg with lifestyle change. **S**
- Lose about 5 percent of body weight before sailing by his own plan of walking, hill work and smaller portions. In progress; target 2026-05-05. **S**
- Medical clearance for the command with a written expedition health plan, medical kit and evacuation plan. In progress; target 2026-05-05. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, hypertension and hyperlipidemia monographs (2026), Aether Forge
- Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update (2024), Wilderness Medical Society (Wilderness Environ Med 2024;35(2):183-197)
- Wilderness Medical Society Clinical Practice Guidelines for the Out-of-Hospital Evaluation and Treatment of Accidental Hypothermia: 2019 Update (2019), Wilderness Medical Society (Wilderness Environ Med 2019;30(4S):S47-S69)
- Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recomm Rep 2021;70(2):1-30)
- Recommendations for medical management of adult lead exposure (2007), Kosnett MJ, et al. (Environ Health Perspect 2007;115(3):463-471)
- Weight Loss to Prevent Obesity-Related Morbidity and Mortality in Adults: Behavioral Interventions (2018), U.S. Preventive Services Task Force

## Follow-up

- Pre-departure visit in four weeks with a basic metabolic panel, vitamin D, PHQ-9 and GAD-7, the second zoster dose, and the medical kit and evacuation plan. **S**
- Next scheduled visit 2026-05-05: pre-departure review two weeks before sailing: blood pressure, medicines and supplies, mental health, vaccinations, the medical kit and the evacuation plan. **S**
